Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Undisclosed Product Type: Small molecule
Deal Size: $4.4 million Upfront Cash: Undisclosed
Deal Type: Funding January 02, 2020
The funding is to support the development of Antabio's novel small molecule candidate for the treatment of Pseudomonas aeruginosa infections in Cystic Fibrosis (CF) patients.